A Clinical Study of YL205 in Patients With Advanced Solid Tumors (NCT06459973)
A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of YL205 in Patients With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Sarah Cannon Research Institute (SCRI)- Denver — Denver, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (43 Sites)
Showing the first 25 of 43 sites.
- Sarah Cannon Research Institute (SCRI)- Denver — Denver, Colorado
- Yale Cancer Center — New Haven, Connecticut
- Florida Cancer Specialists - Lake Mary — Lake Mary, Florida
- Norton Cancer Institute — Louisville, Kentucky
- Washington University School of Medicine - Center for advanced Medicine — St Louis, Missouri
- Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley — Las Vegas, Nevada
- Southwest Women's Oncology — Albuquerque, New Mexico
- Stephenson Cancer Center (Oklahoma) — Oklahoma City, Oklahoma
- Providence Cancer Institute - Franz Clinic — Portland, Oregon
- Sarah Cannon Research (SCRI)-Tennessee — Nashville, Texas
- University of Washington — Seattle, Washington
- Fujian Provincial Cancer Hospital — Fuzhou, Fujian
- Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University — Guangzhou, Guangdong
- Guangxi Medical University Cancer Hospital — Nanning, Guangxi
- Hainan General Hospital — Haikou, Hainan
- The Fourth Hospital of Hebei Medical University — Shijiazhuang, Hebei
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang
- Anyang Cancer Hospital — Anyang, Henan
- Henan Cancer Hospital — Zhengzhou, Henan
- Jingzhou First People's Hospital — Jingzhou, Hubei
- Hubei Cancer Hospital — Wuhan, Hubei
- Tongji Medical College of Hust TongJi Hospital — Wuhan, Hubei
- Union hospital Tongji Medical Colllege Huazhong University of School and Technology — Wuhan, Hubei
- Zhongnan Hospital of Wuhan University — Wuhan, Hubei
- Hunan Provincial Cancer Hospital — Changsha, Hunan
📞 Contact the Study Coordinator
Phone: (615) 329-7274
Email: clinicaltrials@medilinkthera.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumors
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma — Scottsdale, Arizona
- A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Orange, California
- QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations — Denver, Colorado
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors — Denver, Colorado
- A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer — Scottsdale, Arizona
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — Los Angeles, California
Explore by condition: All Advanced Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.